To determine the efficacy of a calcineurin inhibitor in combination with mycophenolate mofetil (MMF) in myeloablative hematopoietic cell transplantation (HCT), we previously conducted a prospective randomized trial comparing CYA and MMF with the standard CYA and MTX for GVHD prophylaxis in myeloablative matched related donor transplants. The results of this trial have been reported and demonstrated faster hematopoietic recovery, decreased mucositis, similar incidence of acute (a)GVHD and comparable survival between MMF and MTX. 1 The study was prematurely closed due to the reduced toxicity of MMF. We now update these data with longer follow-up, and report survival, relapse, infection and GVHD outcomes observed in this study.
Patient and disease characteristics were as previously reported 1 (Table 1) . Briefly, 40 patients were enrolled, with 21 randomized to receive MMF and 19 receiving MTX. All received a myeloablative HCT from a 6/6 HLA-matched related donor, with BM as the hematopoietic cell source. The preparative regimen consisted of BU (16 mg/kg orally) and CY (120 mg/kg). All patients received 300 mg/m 2 CYA intravenously daily from day À 1, and then orally, adjusted to maintain a therapeutic trough level of 200. Patients randomized to MTX received a dose of 5 mg/m 2 intravenously on days þ 1, þ 3, þ 6 and þ 11. Patients randomized to MMF received 500 mg three times daily from day þ 1 until day þ 100.
The median follow-up in the MMF arm is 108 months and 124 months in the MTX arm. As originally reported, there were no significant differences in grade II-IV or III-IV aGVHD between the two groups. The incidence of chronic (c)GVHD was similar (P ¼ 0.53), with a 2-year incidence of 47.6% in the MMF arm compared with 52.6% in the MTX group (Figure 1a ). There were no statistically significant differences in the onset of cGVHD or specific organ involvement. In the MMF and MTX groups, there were seven and eight (33.3% vs 42.1%, respectively) patients classified as having extensive cGVHD (Figure 1b) , and three patients in both the groups (14.3% vs 15.8%) with limited cGVHD. Of the current long-term survivors of the MMF arm, updated using the NIH cGVHD Consensus Criteria 2 three have mild cGVHD of the skin or upper GI tract, and one has moderate cGVHD involving the skin, fascia and vulva. In the MTX arm, three patients have mild cGVHD involving the skin and eye or mouth. Only three patients in total, two in the MMF group and one in the MTX group, remain off all immunosuppression without GVHD.
The incidence of infections was similar in both the groups (P ¼ 0.66 CMV; P ¼ 0.93 non-CMV). The 1-year incidence of CMV viremia was 66.7% in the MMF arm vs 52.6% with MTX, which did not change over the period of follow-up. The 1-year incidence of non-CMV infection was also similar, 52.4% MMF and 52.6% MTX.
There was no difference in bacterial infections. Invasive fungus was rare in both the groups.
Although sample size was small, we previously reported no differences in survival or relapse at 6 months. On long-term follow-up, there remains no significant difference in relapse (P ¼ 0.42) or survival (P ¼ 0.70). One-and five-year relapse was 33.3% and 38.1% in the MMF arm vs 36.8% and 57.9% with MTX ( Figure 1c) . One-and five-year OS was 38.1% and 28.6% with MMF vs 52.6% and 21.0% in the MTX arm (Figure 1d ). Eight patients (38%) died of relapse in the MMF arm vs 7 (37%) in the MTX arm (P ¼ 0.86). There were five deaths from GVHD in the MMF and four in the MTX groups (P ¼ 0.70).
Our previous study demonstrated that the combination of CYA and MMF resulted in decreased mucositis and faster engraftment compared with CyA and MTX, with no significant differences in aGVHD, survival, or relapse at 6 months. Now with longer followup, we also conclude that cGVHD, infections and late mortality were also not significantly different.
While several studies have attempted to use different classes and combinations of immunosuppressive agents, MTX, in combination with a calcineurin inhibitor, remains the standard. While most institutions use MTX at 15 mg/m 2 on day þ 1, followed by 10 mg/ m 2 on days þ 3, þ 6 and þ 11, this study used a 'mini' dose of MTX consisting of 5 mg/m 2 on days þ 1, þ 3, þ 6 and þ 11. This reduced dose was originally developed to decrease the risk of mucosal and hepatic complications, 3 and has been shown to be effective as GVHD prophylaxis with historically similar outcomes as standard doses. [4] [5] [6] The reduced dose of MTX, however, has never been directly compared with the standard dose of MTX, and in our study, mucositis was unfortunately still more common and severe with the 'mini' MTX than with MMF.
MMF inhibits the proliferation of T-and B-lymphocytes and is synergistic with calcineurin inhibitors in preventing GVHD 7 MMF is generally well tolerated, although the optimal dose remains unclear, with some centers administering it two or three times daily. 8 In our study, we used MMF 500 mg three times daily. Others have suggested a dose of 45 mg/kg/day, with similar rates of GVHD compared with historical outcomes. 9 There are few data regarding the use of MMF in myeloablative transplants, although it is an attractive alternative.
Over the last two decades there have been many proposed strategies to prevent GVHD. Small randomized trials such as this one have shown comparable outcomes with non-MTX-based regimens compared with the MTX standard. A recently reported large multi-center randomized trial compared tacrolimus/sirolimus with tacrolimus/MTX after related donor transplants. 10 The trial demonstrated no difference in aGVHD survival, relapse or OS, and tacrolimus/sirolimus led to faster engraftment, less severe aGVHD and oral mucositis, at the cost of higher rates of veno-occlusive disease and thrombotic microangiopathy. While there are clearly trade-offs to different GVHD prophylaxis, there remains a need to determine the optimal regimen for individual patients. Many factors have an impact on transplant and GVHD outcomes, including the influence and interaction of conditioning regimen, donor source, graft type, as well as disease risk profile, prior therapy, history of mucositis and individual patient drug metabolism gene polymorphisms. Determining who benefits from which GVHD prevention regimen requires larger analyses to study specific subsets of patients. Survival (%) Figure 1 . Cumulative incidence of chronic GVHD, relapse and survival curves between MMF and short-course MTX-based GVHD prophylaxis regimens. The cumulative incidence of (a) any chronic GVHD, (b) extensive chronic GVHD, (c) relapse and (d) OS.
